No recent analyst price targets found for HLTRF.
Latest News for HLTRF
HLS Therapeutics Q2 Earnings Call Highlights
HLS Therapeutics TSE: HLS reported second-quarter fiscal 2026 revenue growth as its cardiovascular portfolio expanded 25% year over year, led by continued gains for Vascepa and the first full quarter of sales for newly launched NILEMDO.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for HLTRF.
Senate Trading
No Senate trades found for HLTRF.
U.S. House Trading
No House trades found for HLTRF.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.